PROK1 and cancer: The 5-year cancer-related survival rates in patients with stage II disease were 93.3% (95% CI 61.3‐99) in the plasma PROK1-positive group and 100% (95% CI 100‐100) in the plasma PROK1-negative group (HR 2.43 [95% CI 0.21‐28.5], P = 0.47, Fig. 4B).